Loading...
Market
What will Zevra Therapeutics' Q4 2024 revenue from Miplyffa sales be?
3
Resolution / Starting Odds
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Zevra Therapeutics' quarterly financial reports
Story
FDA Approves Zevra's Miplyffa, First Treatment for Niemann-Pick Disease Type C, Valued at $150 Million
Sep 20, 2024, 03:42 PM
The U.S. Food and Drug Administration (FDA) has approved Zevra Therapeutics' drug, Miplyffa (arimoclomol), for the treatment of Niemann-Pick disease type C (NPC). This approval marks the first treatment for this rare and fatal genetic disorder. The approval also makes Zevra eligible to receive a Priority Review Voucher, valued at approximately $150 million. Miplyffa is approved for use in combination with miglustat for patients aged 2 and older. The New Drug Application (NDA) for arimoclomol had a PDUFA date of September 21, 2024. The US FDA noted that this is the first treatment to get a nod for the condition.
View original story
Similar markets
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Yes • 50%
No • 50%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%